Posted on May 30, 2012 by Sitemaster
According to media releases from the relevant companies, two significant trials (of enzalutamide and of cabozantinib) are already or will soon be recruiting men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: cabozantinib, castration-resistant, enzalutamide, MDV3100, metastatic, XL184 | Leave a comment »
Posted on November 14, 2011 by Sitemaster
Additional data about the effectiveness and safety of cabozantinib were reported over the past weekend at a meeting in San Francisco. … READ MORE …
Filed under: Drugs in development, Management, Treatment, Uncategorized | Tagged: cabozantinib, castration-resistant, mCRPC, metastatic, XL184 | 2 Comments »
Posted on August 25, 2011 by Sitemaster
A new article on the CancerNetwork.com web site has provided a detailed update on the development of cabozantinib (also known as XL184) for the treatment of late stage prostate cancer. … READ MORE …
Filed under: Drugs in development | Tagged: cabozantinib, XL184 | 2 Comments »
Posted on June 6, 2011 by Sitemaster
A new update was provided at the ASCO meeting today on progress from the Phase II clinical trial of XL184 (cabozantinib) in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development | Tagged: cabozantinib, outcome, XL184 | 2 Comments »
Posted on February 18, 2011 by Sitemaster
At the Genitourinary Cancers Symposium yesterday afternoon, new data were presented from Phase II studies of tasquinimod and cabozatinib (XL184) … READ MORE …
Filed under: Drugs in development, Management | Tagged: cabozatinib, ipilimumab, tasquinimod, XL184 | 1 Comment »
Posted on November 18, 2010 by Sitemaster
According to a media release issued this morning by Exelexis, Inc. (a San Francisco-based biotech company), a development stage drug, XL184, has shown clinically significant effects in an early stage clinical trial in men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development | Tagged: castration-resistant, Exelexis, mCRPC, metastatic, XL184 | 5 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 